431 related articles for article (PubMed ID: 30356297)
1. Screening for persistent high-risk HPV infections may be a valuable screening method for young women; A retrospective cohort study.
Ebisch RMF; Ketelaars PJW; van der Sanden WMH; Schmeink CE; Lenselink CH; Siebers AG; Massuger LFAG; Melchers WJG; Bekkers RLM
PLoS One; 2018; 13(10):e0206219. PubMed ID: 30356297
[TBL] [Abstract][Full Text] [Related]
2. HPV detection rates and histopathologic follow-up of patients with HSIL cytology in a large academic women's hospital laboratory.
Ashman D; Zhang H; Li J; Austin M; Wang T; Pradhan D; Zhao C
J Am Soc Cytopathol; 2020; 9(6):550-555. PubMed ID: 32475726
[TBL] [Abstract][Full Text] [Related]
3. Introduction of liquid-based cytology and human papillomavirus testing in cervical cancer screening in Luxembourg.
Latsuzbaia A; Hebette G; Fischer M; Arbyn M; Weyers S; Vielh P; Schmitt F; Mossong J
Diagn Cytopathol; 2017 May; 45(5):384-390. PubMed ID: 28247516
[TBL] [Abstract][Full Text] [Related]
4. Immediate histopathologic follow-up of cervista and aptima high-risk HPV assays in women with LSIL cytology.
Zhang H; Varma KR; Han M; Matsko J; Zhao C
Cancer Cytopathol; 2018 Aug; 126(8):525-532. PubMed ID: 29797678
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in the Republic of Korea, 2014-2016.
Ouh YT; Min KJ; Cho HW; Ki M; Oh JK; Shin SY; Hong JH; Lee JK
J Gynecol Oncol; 2018 Jan; 29(1):e14. PubMed ID: 29185272
[TBL] [Abstract][Full Text] [Related]
6. Molecular Pap smear: HPV genotype and DNA methylation of ADCY8, CDH8, and ZNF582 as an integrated biomarker for high-grade cervical cytology.
Shen-Gunther J; Wang CM; Poage GM; Lin CL; Perez L; Banks NA; Huang TH
Clin Epigenetics; 2016; 8(1):96. PubMed ID: 27651839
[TBL] [Abstract][Full Text] [Related]
7. Low-grade squamous intraepithelial lesion on Papanicolaou test: follow-up rates and stratification of risk for high-grade squamous intraepithelial lesion.
Rufail M; Lew M; Pang J; Jing X; Heider A; Cantley RL
J Am Soc Cytopathol; 2020; 9(4):258-265. PubMed ID: 32402830
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus type-specific persistence and reappearance after successful conization in patients with cervical intraepithelial neoplasia.
Kudoh A; Sato S; Itamochi H; Komatsu H; Nonaka M; Sato S; Chikumi J; Shimada M; Oishi T; Kigawa J; Harada T
Int J Clin Oncol; 2016 Jun; 21(3):580-7. PubMed ID: 26614089
[TBL] [Abstract][Full Text] [Related]
9. Performance of HPV DNA testing with hybrid capture 2 in triaging women with minor cervical cytologic abnormalities (ASC-US/LSIL) in Northern Thailand.
Khunamornpong S; Settakorn J; Sukpan K; Srisomboon J; Suprasert P; Siriaunkgul S
Asian Pac J Cancer Prev; 2014; 15(24):10961-6. PubMed ID: 25605209
[TBL] [Abstract][Full Text] [Related]
10. Safety of screening with Human papillomavirus testing for cervical cancer at three-year intervals in a high-risk population: experience from the LAMS study.
Derchain SF; Sarian LO; Naud P; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Serpa-Hammes L; Matos J; Gontijo RC; Bragança JF; Lima TP; Maeda MY; Lörincz A; Dores GB; Costa S; Syrjänen S; Syrjänen K
J Med Screen; 2008; 15(2):97-104. PubMed ID: 18573778
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of high-risk HPV Hybrid Capture II (hrHPV HC2) test using SurePath(TM) specimens in the prediction of cervical high-grade squamous lesions.
Zhou F; Pulinthanathu R; Elgert P; Cangiarella J; Simsir A
Diagn Cytopathol; 2015 May; 43(5):381-7. PubMed ID: 25546355
[TBL] [Abstract][Full Text] [Related]
13. High-risk human papillomavirus messenger RNA testing in physician- and self-collected specimens for cervical lesion detection in high-risk women, Kenya.
Ting J; Mugo N; Kwatampora J; Hill C; Chitwa M; Patel S; Gakure H; Kimani J; Schoenbach VJ; Poole C; Smith JS
Sex Transm Dis; 2013 Jul; 40(7):584-9. PubMed ID: 23965776
[TBL] [Abstract][Full Text] [Related]
14. Are vaginal swabs comparable to cervical smears for human papillomavirus DNA testing?
Coorevits L; Traen A; Bingé L; Van Dorpe J; Praet M; Boelens J; Padalko E
J Gynecol Oncol; 2018 Jan; 29(1):e8. PubMed ID: 29185266
[TBL] [Abstract][Full Text] [Related]
15. Clinical performance of the Food and Drug Administration-Approved high-risk HPV test for the detection of high-grade cervicovaginal lesions.
Zhou H; Mody RR; Luna E; Armylagos D; Xu J; Schwartz MR; Mody DR; Ge Y
Cancer Cytopathol; 2016 May; 124(5):317-23. PubMed ID: 26774025
[TBL] [Abstract][Full Text] [Related]
16. Urine collection in cervical cancer screening - analytical comparison of two HPV DNA assays.
Tranberg M; Jensen JS; Bech BH; Andersen B
BMC Infect Dis; 2020 Dec; 20(1):926. PubMed ID: 33276740
[TBL] [Abstract][Full Text] [Related]
17. Can the careHPV test performed in mobile units replace cytology for screening in rural and remote areas?
Lorenzi AT; Fregnani JH; Possati-Resende JC; Antoniazzi M; Scapulatempo-Neto C; Syrjänen S; Villa LL; Longatto-Filho A
Cancer Cytopathol; 2016 Aug; 124(8):581-8. PubMed ID: 27070446
[TBL] [Abstract][Full Text] [Related]
18. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
[TBL] [Abstract][Full Text] [Related]
19. Correlation of p16INK4a immunoexpression and human papillomavirus (HPV) detected by in-situ hybridization in cervical squamous neoplasia.
Cheah PL; Koh CC; Nazarina AR; Teoh KH; Looi LM
Malays J Pathol; 2016 Apr; 38(1):33-8. PubMed ID: 27126662
[TBL] [Abstract][Full Text] [Related]
20. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
